Metabolic fate of ^{13}C -labelled polydextrose and impact on the gut microbiome: A triple-phase study in a colon simulator

Lamichhane, Santosh; Yde, Christian C.; Max Jensen, Henrik; Morovic, Wesley ; Hibberd, Ashley A. ; Ouwehand, Arthur C.; Saarinen, Markku T. ; Forssten, Sofia D.; Wiebe, Lars; Marcussen, Jørn

Total number of authors:
14

Published in:
Journal of Proteome Research

Link to article, DOI:
[10.1021/acs.jproteome.7b00683](https://doi.org/10.1021/acs.jproteome.7b00683)

Publication date:
2018

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):

Lamichhane, S., Yde, C. C., Max Jensen, H., Morovic, W., Hibberd, A. A., Ouwehand, A. C., Saarinen, M. T., Forssten, S. D., Wiebe, L., Marcussen, J., Bertelsen, K., Meier, S., Young, J. F., & Bertram, H. C. (2018). Metabolic fate of ^{13}C -labelled polydextrose and impact on the gut microbiome: A triple-phase study in a colon simulator. *Journal of Proteome Research*, 17(3), 1041-1053. <https://doi.org/10.1021/acs.jproteome.7b00683>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

3 Santosh Lamichhane,^{1, 7*} Christian C. Yde,^{1,4} Henrik Max Jensen,⁴ Wesley Morovic,⁸ Ashley A.
4 Hibberd,⁸ Arthur C. Ouwehand,³ Markku T. Saarinen,³ Sofia D. Forssten,³ Lars Wiebe,⁵ Jørn
5 Marcussen,⁴ Kresten Bertelsen,^{4,9} Sebastian Meier,⁶ Jette F. Young,¹ and Hanne Christine
6 Bertram¹

21 Email: santosh.lamichhane@utu.fi or lamichhane17@gmail.com, Phone: +358 2299070

22

Abstract

The present study introduces a novel triple-phase (liquids, solids and gases) approach, which employed uniformly labelled [U- ^{13}C] polydextrose (PDX) for the selective profiling of metabolites generated from dietary fiber fermentation in an *in vitro* colon simulator using human fecal inocula. Employing ^{13}C NMR spectroscopy, [U- ^{13}C] PDX metabolism was observed from colonic digest samples. The major ^{13}C -labelled metabolites generated were acetate, butyrate, propionate, and valerate. In addition to these short-chain fatty acids (SCFAs), ^{13}C -labelled lactate, formate, succinate, and ethanol were detected in the colon simulator samples. Metabolite formation and PDX substrate degradation were examined comprehensively over time (24 and 48 hours). Correlation analysis between ^{13}C NMR spectra and gas production confirmed the anaerobic fermentation of PDX to SCFAs. In addition, 16S rRNA gene analysis showed that the level of *Erysipelotrichaceae* was influenced by PDX supplementation and *Erysipelotrichaceae* level were statistically correlated with SCFA's formation. Overall, our study demonstrates a novel approach to link substrate fermentation and microbial function directly in a simulated colonic environment.

Keywords. Gut microbiome, Dietary fiber, ^{13}C -labelled metabolites, ^{13}C NMR

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

40 **Introduction**

41 The human gut harbours a complex microbial ecosystem, and the gut microbial activity has been

42 recognized as a pivotal regulator of the host metabolism.¹⁻⁴ Recent evidence revealing that gut

43 microbial activity can be influenced by dietary fiber (i.e. non-digestible food ingredients), has led

44 to an increased demand for evaluation of the specific functions of these ingredients in the gut.⁵⁻⁷

45 Polydextrose (PDX), which is used as functional ingredient in a variety of foods, is a highly

46 branched and complex polymer of glucose. PDX is a soluble fiber produced by thermal

47 condensation of glucose and possesses prebiotic effects as a food ingredient.⁸⁻⁹ An understanding

48 of the microbial composition and metabolism is fundamental to evaluate the effects of dietary

49 fibers in the gut. In addition, evaluating the selective microbial products formed from the

50 substrate is key to directly linking gut microbial activity and health benefit of any particular

51 dietary fiber. Stable isotope labelling provides an excellent approach for tracking the conversion

52 of the substrate and identifying resultant metabolic products, thus allowing a rapid and

53 comprehensive profiling of selective microbial activity.¹⁰ An approach using uniformly labelled

54 [U-¹³C] substrate also offers a robust method to elucidate the metabolic pathways involved in the

55 microbial metabolism. In fact, previous studies based on stable isotope labelling have shown the

56 usefulness of [U-¹³C] approaches. For instance, de Graaf et al. introduced ¹³C enrichment as an

57 approach to evaluate the kinetics of ¹³C-labelled glucose fermentation in an *in vitro* colon

58 model.¹¹⁻¹³

59

60 To characterize the metabolic process of dietary fiber catabolism, an *in vitro* colon simulator

61 offers the advantage of enabling dynamic sampling and implying substantially less ethical issues

62 compared to an *in vivo* study. On that account, an *in vitro* colon model could be a robust

3

ACS Paragon Plus Environment

approach to profile the complete set of ^{13}C -labelled metabolites produced during the microbial fermentation processes. Nuclear magnetic resonance (NMR) or mass spectrometry (MS) is often used to measure the isotopically labelled metabolites in biological samples. An NMR-based approach can directly detect an isotopic label in the molecule and distinguish different isotopomers, whereas MS-based techniques requires complicated protocols with different ionizations and derivatization steps to obtain information on the isotopomer.¹¹ Nevertheless, both analytical platforms provide complementary information. In this study, we employed a combination of liquid and solid state NMR to characterize the fate of uniformly labelled $[\text{U-}^{13}\text{C}]$ PDX catabolism by gut microbiota in a four-stage *in vitro* colon simulator model. Concomitantly, gas chromatography (GC) coupled with MS was used to monitor the gas generated during PDX catabolism. In addition, 16S rRNA gene amplicon sequencing was performed to identify and compare the microbial composition within the given sample sets. Overall, the aim was to measure the selective metabolic and microbial changes occurring in the colon simulator using uniformly labelled $[\text{U-}^{13}\text{C}]$ PDX as a substrate for gut microbes.

1
2
3 86 **Material and methods**

4
5
6 87 **Human colon simulator**

7
8 88 The *in vitro* simulator used for the study models the human large intestine (Figure 1A). This
9
10 89 anaerobic *in vitro* colon model has been used to investigate the fermentation, and function of
11
12 90 prebiotic and probiotic ingredients.^{6, 14-15} Mäkituokko et al. have previously described the
13
14 91 technical specification of this *in vitro* model.¹⁶ Briefly, the simulator used for the study consists
15
16 92 of eight separate units, each containing four semi-continuously connected glass vessels. The
17
18 93 vessels in each unit (V1 to V4) model the ascending (V1), transverse (V2), descending (V3) and
19
20 94 sigmoidal (V4) parts of the human colon, respectively. In the initial phase of the simulation, each
21
22 95 unit is inoculated with pre-incubated fecal inoculum obtained from a fresh human fecal sample,
23
24 96 which forms the microbiota of the colonic model. These fecal inoculums are prepared with three
25
26 97 parts (w/v) of anaerobic simulator medium, incubated anaerobically for 24 hours at 37 ° C
27
28 98 (details in¹⁶). In this study, three healthy Finnish volunteers provided the fecal samples for
29
30 99 inoculum. According to Finnish law, no ethical approval was required, since there has not been
31
32 100 any interference with a person's physical or mental integrity. During simulation, the fecal
33
34 101 inoculum from one volunteer was used, and the system was fed with a synthetic ileal medium in
35
36 102 three-hour cycles to simulated colon model for 24 or 48 hours, during which transition of
37
38 103 fermented fluids and microbes and feeding of fresh medium occurred. As test substance, 2%
39
40 104 PDX with natural isotope abundance (Litesse Ultra; Danisco UK, Redhill, U.K.) or 2% [U-¹³C]-
41
42 105 PDX (Danisco Denmark, Grindsted, Denmark) was added to the synthetic ileal medium used as
43
44 106 feeding solution. The syntetic ileal medium without addition of any PDX was used as a control
45
46 107 (CTRL). The synthetic ileal medium was used as a control (CTRL). The simulations were
47
48 108 performed at DuPont, Nutrition and Health, Kantvik, Finland. To track the microbial activity
49
50
51
52
53
54
55
56
57
58
59
60

over time, the microbial slurry and gas were collected from all vessels (V1-V4) after 24 and 48 hours of simulation. In total, 72 ($3_{\text{donors}} * 4_{\text{vessels (V1-V4)}} * 2_{\text{time points (24 and 48 hours)}} * 3_{\text{without PDX (CTRL)/2\% PDX/ 2\% [U-13C] - PDX}}$) samples were collected from the *in vitro* colon simulator and stored at -80 °C prior to analysis.

Preparation of simulated fecal water samples

The collected fecal slurry samples from the simulator were homogenized by vortex mixing for 1 min, and then centrifuged at 5,000 g for 10 minutes at 4 °C (Eppendorf 5471, USA). The supernatants were removed carefully and subsequently lyophilized. The sample pre-treatment (adjusting the pH $\geq$ 7) before lyophilisation was carried out as recommended by Jacobs et al.¹⁷ The remaining pellets were stored at -80°C for solid-state NMR analysis. Lyophilized fecal samples were reconstituted in D₂O and the samples were homogenized by vortex mixing and then centrifuged at 10,000 g for 10 minutes at 4 °C.

Spectroscopic analyses

Liquid-state NMR

A volume of 600 μ L supernatant containing 0.025 mg/mL 3-trimethylsilyl propionic acid-*d*₄ sodium salt (TSP) as reference compound was transferred to a 5 mm NMR tube. One-dimensional ¹³C NMR experiments were acquired using a Bruker Avance III 800 MHz spectrometer equipped with a 5-mm ¹H observe TCI cryoprobe (Bruker Biospin, Rheinstetten, Germany) at 25°C. A standard pulse sequence using power-gated decoupling and 30° flip angle was used (zgpg30). Acquisition parameters for the spectra were 128 scans, a spectral width of 48077 Hz collected into 64 K data points, an acquisition time of 0.68 s and an inter-scan

132 relaxation delay of 5 s. The Free Induction Decay (FID) obtained was multiplied by 1 Hz of
133 exponential line broadening before Fourier transformation. The spectra were referenced to TSP
134 (chemical shift defined at 0 ppm), phased, and baseline corrected in Topspin 3.0 software.
135 Assignments of ^{13}C NMR signals were carried out according to the Human Metabolome
136 Database.¹⁸ In addition, an HSQC experiment was acquired with a spectral width of 11961 Hz in
137 the ^1H dimension and 33276 Hz in the ^{13}C dimension, a matrix with a size of 1024×128 complex
138 data points, 2 transients per increment and a relaxation delay of 1.5 s. Besides 1D carbon spectra,
139 ^{13}C positional enrichment were confirmed by ^1H NMR spectroscopy (^{13}C decoupled and ^{13}C
140 coupled spectra) using a Bruker Avance III 500 MHz spectrometer equipped with a 5 mm triple
141 resonance (TXI) probe at 25°C (experiment details in Supporting information (SI)).

142 **Solid-state NMR**

143 The pellets obtained from the *in vitro* colon fecal slurry were analyzed using cross-polarization
144 magic-angle spinning (CP MAS) NMR. Lyophilized pellet samples (mean sample weight: 29.38
145 mg) were powdered and packed in 4-mm diameter zirconium rotors (Bruker Biospin,
146 Rheinstetten, Germany). ^{13}C CP MAS NMR spectra were acquired on a Bruker Avance III 600
147 MHz spectrometer equipped with a $^1\text{H}/^{13}\text{C}$ CP MAS probe with gradient aligned along the magic
148 angle. For acquisition of ^{13}C CP MAS NMR spectra, a contact time of 0.5 ms, a proton field of
149 approximately 45 kHz during CP and data acquisition, a relaxation delay of 2 s and a spinning
150 speed of 14 kHz were employed. The FID was multiplied by 50 Hz of exponential line
151 broadening before Fourier transformation. The spectra were phased, and baseline corrected using
152 Bruker Topspin 3.0 software.

153 **LC-MS analysis**

The HP-LC was operated at a flow rate of 12 $\mu\text{L}/\text{min}$, and the mobile phase consisted of solution A (0.1% HCO_2H in water) and solution B (0.1% HCO_2H in ACN). For all analyses, 1 μL of calibrant (sodium formate) and sample were used. The samples were separated by an eclipse plus phenyl C18 column (Agilent Technologies, Waldbronn, Germany), using the following gradient: 2% B for 4 min, linear gradient of 2-60% B in 10 min, 60-90% B in 3 min, 90% B for 2 min, 90-2% B in 1 min, and 2% B for 10 min. MS was operated in both negative and positive ion mode. The mass range was set from 40 to 800 m/z , and data were acquired in profile mode at a frequency of 1 Hz with active focus mode off. The raw data were automatically calibrated using the sodium formate cluster signals and required m/z values were integrated in the data analysis software package Compass HyStar (Bruker Daltonics, Bremen, Germany).

164

165 **CO_2 analysis by GC-MS**

166 CO_2 analysis was performed using an Agilent Technologies 6890N/5975C GC-MS system. A total of 250 μL sample was injected (split ratio 1:150) using a 2.5 mL heated syringe (50 $^\circ\text{C}$), into a 50 m (L) x 0.25 mm (ID) x 0.25 μm (df) FFAP column (Quadrex, Bethany, CT 06524 USA), kept at 30 $^\circ\text{C}$. Helium was used as carrier gas at 1 mL/min. The sampling needle was flushed with He between sample injections to avoid interference from air and from the previous sample. The MS was used in full scan mode (scan range 10 – 100 amu) with electron ionization (70 eV). The selected ions were $m/z=44$ for $^{12}\text{CO}_2$ and $m/z=45$ for $^{13}\text{CO}_2$ with retention time of 161 s. Argon (Ar) with $m/z=40$ was used as a reference gas for relative quantification of the gases.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

Metabolite data analysis

¹H NMR spectra were imported into Matlab R2014b (The Mathworks, Inc., USA) and the misalignments of the spectra were corrected using the icoshift algorithm based on the correlational shifting of spectral intervals.¹⁹ The spectra were mean centered and pareto-scaled before principal component analysis (PCA). PCA was performed using the PLS Toolbox (Eigenvector Research, USA) in MATLAB R2014b. Relative quantification of selected ¹³C resonances were performed by integration of peak areas in MATLAB R2014b. Spearman correlation coefficient between the integrals of these metabolites was calculated using the statistical toolbox in Matlab R2014b. The results were illustrated by heat maps using MATLAB R2014b

Extraction and quantification of bacterial DNA

The DNA from the simulation samples was extracted and purified with an automated MagMAX™ Sample Preparation System (Life Technologies, Halle, Belgium), using the MagMAX™ Nucleic Acid Isolation Kit. The amount of extracted DNA was determined by a Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific, Vantaa, Finland). Concurrently, non-template negative controls were processed to detect possible contamination.

16S rRNA gene amplicon sequencing and microbiome data analysis

The V4 region of the 16S rRNA gene communities was amplified using a PCR workflow as previously described.²⁰ Purified amplicons were pooled and sequenced using 2 x 250 base pair (bp) Paired-End Illumina MiSeq (Pioneer, Johnston, IA). Resulting sequencing data were analyzed using the Quantitative Insights into Microbial Ecology (QIIME, v. 1.9.1) pipeline.²¹

9

ACS Paragon Plus Environment

1
2
3 197 Sequencing reads were joined using fastq-join²² with a minimum 200 bp overlap and 5%
4
5 198 maximum difference, de-multiplexed, and quality filtered using a Phred threshold of >20.
6
7 199 Sequences were clustered into operational taxonomic units (OTUs) at 97% similarity with
8
9 200 uclust²³ using an open reference scheme against the Greengenes database,²⁴ where non-matching
10
11 201 reads were retained and clustered *de novo*. Sequences were aligned with PyNAST²⁵ and the
12
13 202 phylogenetic tree used for downstream analysis was generated using FastTree.²⁶ Samples were
14
15 203 normalized for sequencing depth by rarefaction at 15,958 reads, and one sample (Simulation II,
16
17 204 Time 48, 2% PDX ¹³C, vessel 1) was removed due to low coverage. α -diversity was assessed by
18
19 205 the phylogenetic diversity whole tree metric²⁷ and compared between groups using non-parametric
20
21 206 t-tests with 999 Monte Carlo permutations. β -diversity was measured using the weighted
22
23 207 UniFrac distance²⁸ and groups were compared with Analysis of Similarities (ANOSIM). Genera
24
25 208 (or higher taxonomic levels if the genus could not be confirmed) comprising >0.2% abundance
26
27 209 were compared between groups using Kruskal-Wallis tests and graphed using Prism 7 (GraphPad
28
29 210 Software, La Jolla, California, USA). P values were adjusted for multiple comparisons with the
30
31 211 Benjamini-Hochberg false discovery rate (FDR) correction and $p < 0.05$ was considered a
32
33 212 significant difference for all tests.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

214 Results and Discussion

215 This work focused on the study of [U-¹³C] labelled PDX as a substrate during microbial
216 digestion and characterization of ¹³C-labelled metabolites in different compartments of an in
217 vitro colon simulator. The ¹³C-labelled metabolites were characterized by liquid-state and solid-
218 state NMR spectroscopy. GC-MS was performed to evaluate the gas generated during [U-¹³C]
219 PDX catabolism. In addition, 16S rRNA gene sequencing was performed to study the phylogeny
220 and taxonomy of the gut microbiome from the *in vitro* gut fermentation.

222 Solution state analysis

223 A significant effect of [U-¹³C] PDX metabolism was observed in ¹³C NMR spectra obtained
224 from colonic digest extracts. When compared to experiments using a natural abundance
225 reference PDX reference, the spectra with [U-¹³C] PDX clearly show the low-molecular-weight
226 compounds generated from carbohydrate metabolism (Figure 1B). The results show that the
227 major ¹³C-labelled metabolites included acetate, butyrate, propionate, and valerate. To map these
228 metabolic changes, peak integrals were obtained from ¹³C NMR spectra and plotted accordingly
229 (SI, Figure S1). Even though an inter-individual variation is apparent, the integrals indicate that
230 the SCFA concentrations gradually increased from the ascending colon (V1) to the descending
231 colon (V3) during the simulation. The overall metabolite concentration decreased in the sigmoid
232 colon part (V4) during 24 hours while it remained stable at 48 hours (SI, Figures S1-S4).
233 Intriguingly, the pattern seen in SCFA formation is supported by the degradation pattern of PDX
234 as the concentration of PDX decreased during simulation from the proximal colon to the sigmoid
235 colon at 48 hours (SI, Figure S3), however, an inter-individual difference between the donors
236 exists mainly at 24 hours. Thus, our result reveal how fiber/substrate availability affects the gut

fermentation pattern and SCFA concentrations in different segments of the gut over time. The present study corroborates that PDX fiber fermentation results in the synthesis of SCFAs as eminent metabolic end products.²⁹ Previous reports from animal models, *in vitro* models, and humans have shown increased fecal levels of butyrate and acetate in subjects after PDX intake.^{16, 30-31} However, none of these studies measured the microbial metabolites derived directly from PDX catabolism. We report a novel approach to determine the specific metabolites generated from PDX fermentation. Furthermore, this *in vitro* study enabled us to directly monitor the dynamics of microbial metabolites formed during PDX fermentation in different parts of the colon at different time point (24 hrs and 48 hrs), while the same information would be practically and ethically impossible to obtain *in vivo* in humans. The result revealed that acetate clearly is the principal SCFA produced, however butyrate is of particular interest as it has been described as a vital metabolite for colon.³²⁻³³ An increase in SCFA production, specifically butyrate formation in the colon simulator, can be considered as the primary metabolic significance of PDX digestion in relation to gut microbial activity and benefits for host. Interestingly, our data also revealed an increased level of valerate from V1 to V4 due to PDX catabolism (for inoculum from subject). Until now, studies focussing on valerate as product of carbohydrate metabolism have been sparse.³⁴⁻³⁶ Although only observed in one subject, our finding indicates a possible direct association between dietary fiber fermentation, valerate formation, and gut microbial activity. However, to validate this hypothesis, other independent studies are needed.

In addition to SCFAs, we identified ¹³C labelled lactate, formate, succinate, and ethanol in the fecal ¹³C NMR spectra. As the colon simulator genuinely allowed dynamic sampling, we comprehensively examined these biochemical changes over time (24 and 48 hours) in the vessels

(SI, Figures S1-S4). The results show that succinate, lactate, and formate mainly appeared in vessel V1 and V2 (ascending and transverse colon) during the fermentation, but an inter-individual difference between the donors was observed. This inter-individual variation can be ascribed to the differential microbial composition between individuals and the result suggests that these metabolites are metabolised further and thus disappear in V3 and V4 (described below). A previous study has shown that lactate can be fermented to SCFAs (mainly butyrate) by human intestinal bacteria.³⁷ Previous work also supports the finding that lactate accumulates at low pH (pH 5.2 likewise in V1 colon simulation) but butyrate and propionate production were initiated at pH 5.9 and 6.4, respectively, equivalent to the pH of descending and sigmoid colon (V3 and V4) in the simulation.³⁸

Similarly, formate is involved in acetate formation via the Wood-Ljungdhal pathway and succinate is a well-known precursor for the formation of propionate through the succinate pathway (Figure 2).²⁹ Interestingly, studies have also shown that when sufficient carbohydrate is present during bacterial metabolism, succinate is accumulated due to a reduced requirement for succinate decarboxylation.³⁹ Figure 2 depicts the possible pathways linked to carbohydrate (PDX) catabolism and metabolites formation in the gut during the anaerobic microbial process. Accumulation of lactate, formate, and succinate (V1 and V2) indicates an imbalance between the production and consumption pathway involved in anaerobic gut metabolism. However, the finding also reflects diverse microbiota composition/activity and potential cross feeding between microbes in the gut simulator.

The structure of the randomly formed PDX is rather complex and is composed of both linear and branched α and β - 1-2, 1-3, 1-4 and 1-6 linkages, dominated by 1-6.⁴⁰⁻⁴¹ The ¹³C spectra

indicated the presence of partly undigested ^{13}C -labelled PDX especially in vessels V1 and V2 alongside metabolic intermediates, while sharper carbohydrate signals emerge especially in vessels V3 and V4. The degradation pattern of residual PDX suggests that vessels V1 and V2 (ascending to transverse colon) had similar metabolic patterns, as did vessels V3 and V4 (descending to sigmoid colon), respectively (Figure 3). In particular, the results indicate that vessels V1 and V2 had residual polysaccharide with broadened signals near 111.5 ppm (β -glucofuranosyl), 106 ppm (predominantly β -gluco-pyranosyl), 104 ppm (levoglucosan (β -1,6 anhydroglucose) and 101 ppm (α -gluco-pyranosyl). Increasingly sharper signals in these regions emerged in vessels V1 to V4 due to polysaccharide degradation to smaller units, which could be ascribed to enzymatic or acid hydrolysis. The glucofuranosyl units are increasingly represented in vessels 3 and 4, possibly due to a lack of efficient enzymes degrading glucofuranosyl linkages. The results show that free glucose also varies in different compartments of the colon simulator.⁴²⁻
⁴³ Our finding is in agreement with a former study where it was reported that glucofuranosyl moiety is accumulated in the final vessel indicating a lesser ability of the microbiota to degrade the glucofuranosyl structure.⁴¹

Solid-state analysis

The residual pellets obtained from the microbial slurry were examined using CP MAS NMR spectroscopy. Figure 4A shows representative ^{13}C CP MAS spectra obtained from the pellet of the anaerobic microbial degradation of PDX during simulation. To our knowledge, this paper presents the first work examining the triple phases in fecal samples (*in vitro* simulation), in particular CP MAS from the fecal slurry (*in vitro* samples) has not been reported before. The CP MAS spectra showed characteristic peaks that can be assigned to the carbohydrate, carbonyl,

CH₂, CH₃, anomeric and aromatic resonances.⁴⁴ The ¹³C MAS NMR spectrum is a sum of [U-¹³C] PDX, ¹³C metabolites, and natural abundance (1%) of ¹³C from major undigested components such as cellulose, ligno-cellulose, undigested protein and fat, and bacterial cell debris. Thus, collectively data provide valuable information about the heterogeneity of microbial activity from proximal to distal section of the gut. As shown in the score plot depicted in Figure 4B, overall the intensity of signals from carbohydrate and anomeric resonances were decreased from vessel V1 to V4 while carbonyl, CH₂, CH₃ resonances were higher in V1 to V3 (ascending to descending colon) and did not noticeably change in V4 (sigmoid colon) indicating that substrate availability affects the gut fermentation pattern. This information is unique and adds to the finding obtained from solution-state NMR.

Gas-state analysis

In general, CO₂ and CH₄ are the products of carbohydrate fermentation during anaerobic microbial metabolism. We detected ¹²CO₂ (m/z 44) and ¹³CO₂ (m/z 45), while CH₄ was not detected. This finding may be explained by the fact that CH₄ is produced only in 30 % -50 % of healthy adults.⁴⁵ As expected, the ratio ¹³CO₂/¹²CO₂ shows a marked difference between the fecal extract with [U-¹³C] PDX or a natural abundance PDX reference (Figure 5). In addition, the heat map (Figure 6) depicts positive correlations between ¹³CO₂/¹²CO₂ ratio and intensity of SCFA signals in the liquid-state ¹³C NMR spectra. In addition, the ¹³CO₂/¹²CO₂ ratio shows negative correlation to certain regions of the PDX signals in ¹³C NMR spectra. GC-MS results are thus consistent with NMR analyses and provide an additional angle to [U-¹³C] PDX catabolism and microbial metabolism in the gut simulator.

329 Microbiome analysis

330 To measure the *in vitro* colonic microbial composition, α -diversity and β -diversity were
331 compared between the groups. The α -diversity measures the OTU diversity within the samples
332 whereas β -diversity measures dissimilarity between each sample pairing at the OTU level. The
333 results showed that α -diversity was only significantly different between simulations performed
334 with inoculum obtained from the donors I/II and I/III (Figure 7A, $p = 0.006$). These groups were
335 compared with a non-parametric t-test using 999 Monte Carlo permutations and the p-value was
336 adjusted using the Benjamini-Hochberg FDR. However, the α -diversity from other
337 simulation/treatment and simulation/time comparisons did not show any significant differences.
338 In contrast, the results depicted that β -diversity was significantly different between simulation
339 times (24 hours and 48 hours) and simulations performed from different donors I, II and III
340 (Figure 7B). The principal coordinate analysis (PCoA) for the weighted UniFrac distance matrix
341 showed significant differences between the simulation from three donors ($p=0.001$) and to a
342 lesser degree simulation time ($p=0.01$), whereas the treatment effect was insignificant
343 ($p=0.1029$).

344 An analysis of genera and higher-level taxonomy between different categories showed few
345 bacterial lineages shifted in relative abundances after the PDX supplementation, with increasing
346 levels of *Erysipelotrichaceae* being most pronounced. The *Erysipelotrichaceae* family was found
347 to be significantly different in control and treatment for all simulations (Figure 8). In addition,
348 the PDX resulted in an increased level of *Bifidobacterium* and in a decreased level of
349 *Lactobacillus*, but these changes were not as prominent as *Erysipelotrichaceae*. Recently,
350 *Erysipelotrichaceae* has gained substantial attention in gut microbial research due to its potential
351 role in host physiology and/or disease conditions.⁴⁶⁻⁴⁸ Evidence support an association

1
2
3 352 between *Erysipelotrichaceae* and metabolic disorders⁴⁷ and inflammation-related disorders of the
4
5 353 gastrointestinal tract.⁴⁸⁻⁴⁹ In addition, studies have shown that diet influences the relative
6
7 354 abundance of *Erysipelotrichaceae* family in the gut.^{47, 50-52} Previous studies have shown positive
8
9 355 correlations between *Erysipelotrichaceae* occurrence and complex carbohydrate consumption.⁵¹⁻
10
11 356 ⁵² The *Erysipelotrichaceae* family is designated as SCFA producers, and some species within
12
13 357 this family are capable of producing butyrate.⁵³⁻⁵⁴ Meanwhile, other studies have shown this
14
15 358 bacterial family to be enhanced from high-fat diets.⁵⁵⁻⁵⁶ This is not unexpected, as identical gut
16
17 359 microbial genera can have both specific and shared systemic effects.⁵⁷⁻⁵⁸ Moreover, our results
18
19 360 substantiate an enrichment of *Erysipelotrichaceae* family during complex carbohydrate (PDX)
20
21 361 fermentation. Specifically, our results suggest that associations between PDX fermentation,
22
23 362 *Erysipelotrichaceae* and SCFA production exist (supported by correlation analysis, heat map
24
25 363 Figure 9), albeit using a limited set of donors. Independent studies with larger samples sets are
26
27 364 required to disclose a possible link, and further analysis at strain levels within
28
29 365 *Erysipelotrichaceae* may expand our current knowledge.⁵⁹
30
31
32
33
34
35
36
37

38 367 **¹³C incorporation and statistical correlation between metabolites and microbiome**

39
40
41 368 LC-MS analysis enabled us to determine the level of isotope incorporation in the SCFAs during
42
43 369 *in vitro* colon simulation. The results indicate that there was clear difference in the ¹³C isotope
44
45 370 incorporation among different subjects and vessels over time. In particular, butyrate showed high
46
47 371 variability when compared to acetate and propionate (SI, Figures S5-S8). Meanwhile, these data
48
49 372 provide an opportunity to explore if any statistical relation between metabolites and microbes in
50
51 373 the colon simulator exists at isotope level. The correlation analysis (Figure 9) between OTUs
52
53 374 (included OUT with zero values reported in ≤ 1 sample) and integrals of the metabolites (m/z
54
55
56
57
58
59
60

from LC-MS analysis) suggests an statistical association between bacterial family *Erysipelotrichaceae*, *Faecalibacterium* and SCFAs. The correlation was found to be significant with *Erysipelotrichaceae* (p value < 0.05) for most of the ^{13}C isotopes from SCFAs. Intriguingly, we did also see that *Erysipelotrichaceae* were increased in PDX treated samples. In fact our finding, is also in agreement with previous findings relating *Erysipelotrichaceae* and *Faecalibacterium* family to SCFA producers.⁵³⁻⁵⁴ In addition, *Blautia* was positively correlated to butyrate. The statistical correlation indicates that both of these bacterial family may be actively involved in the PDX fermentation and butyrate formation in the colon simulator. In fact, previous studies have reported *Blautia* and *Clostridiales* to be a common bacterial genus in the human gut belonging to a butyrate-producing bacterial species.⁶⁰⁻⁶¹ However, we saw negative correlation between *Clostridiales* and butyrate. The discrepancy might be linked to higher abundance of *Erysipelotrichaceae* which possibly dominated the butyrate production in the *in-vitro* colon.

Likewise, ^{13}C incorporation of propionate was positively correlated to *Parabacteroides* and *Bacteroidetes*. The phylum *Bacteroidetes* has been reported to be major propionate produce, even though it could also produce acetate and butyrate.⁶²⁻⁶³ Furthermore, we saw negative correlation between *Bifidobacterium* and ^{13}C labelled butyrate (Figure 9). *Bifidobacterium* are well known carbohydrate degraders but they are antioxidants, polyphenols, and conjugated linoleic acids producers.⁶⁴⁻⁶⁵ The negative association seen here may be indication of cross feeding interactions between *Bifidobacterium* and butyrate-producing colon bacteria.⁶⁶ However, the underlying relation is not yet clear. These findings may be corroborated from future studies using more donors. Taken together, our findings substantiate the association of various microbes

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

with fermented gut microbial products. Here, we provide a novel methodological approach to study gut microbial function using stable isotope tracking. This approach could enable in-depth functional microbial analyses by directly linking substrate fermentation and microbial function in the gut system.

Conclusion

Overall, the present study showed that the application of a triple-phase study (solid, liquid, and gas) combined with ¹³C labelling monitors the overall and specific metabolites derived directly from in vitro colonic PDX catabolism. The correlation between ¹³C NMR spectra and ¹³C CO₂ production substantiates the anaerobic fermentation of PDX to SCFAs. Furthermore, the 16S rRNA gene analysis depicted that *Erysipelotrichaceae*, a butyrate-producing bacterial lineage changed in relative abundance after the PDX supplementation in the *in vitro* colon simulator. Further, statistical correlation analysis showed that *Erysipelotrichaceae* and *Blautia* is positively correlated to ¹³C SCFAs while the *Parabacteroides* is linked to ¹³C propionate formation from PDX metabolism in an *in vitro* colon simulator. Overall, the study proposes a novel approach to link substrate fermentation and microbial function directly in a simulated gut system.

ASSOCIATE CONTENT

SUPPORTING INFORMATION

The following associated information is available free of charge on ACS publications website
Supplementary methods on ¹H NMR experiments.
Figure S1-S4: Integrals of ¹³C labelled acetate, ¹³C labelled butyrate, ¹³C labelled propionate, ¹³C labelled succinate, ¹³C PDX region 1 (104.5-103.9ppm), ¹³C labelled lactate, ¹³C valerate and ¹³C

labelled formate obtained from each vessel (V1 to V4) representing different areas of the colon i.e. proximal to the distal part in the colon simulator.

Figure S5 showing the representative MS spectra showing the m/z ratio for acetate, propionate and butyrate. Figure S6-S8 illustrating the ^{13}C incorporation at isotopic level in the butyrate, acetate and propionate for three donors at 24 and 48 hours.

FUNDING SOURCES

The present study is part of the Ph.D. work of Santosh Lamichhane and was financially supported by DuPont, Food Future Innovation (FFI), and Aarhus University. “Advances in food and nutrition research through implementation of metabolomics technologies” (Grant No. 274-09-0107).

ACKNOWLEDGEMENT

The 800 MHz spectra NMR spectra were obtained at the Danish Instrument Center for NMR spectroscopy of Biological Macromolecules. Mr. Kim Blauenfeldt Gosmers from DuPont, Aarhus, and Dr. Morten Rahr Clausen from Aarhus University are thanked for help during GC and LC-MS analysis, respectively. Ms. Kirsi Stenström (DuPont Nutrition and Health, Finland) is acknowledged for help with the colon simulations and DNA extraction. Ms. Paige Roos at DuPont Pioneer is acknowledged for performing amplicon sequencing.

AUTHOR INFORMATION

Santosh Lamichhane, Email: santosh.lamichhane@utu.fi or lamichhane17@gmail.com. Phone: +358 2299070

Figure Captions

Figure 1. The *in vitro* colon simulator and representative ^{13}C NMR spectra obtained from the colon simulation. A) Schematic depiction of the *in vitro* colon simulator. Each vessel (V1–V4) in colon simulator models the different compartments of the human colon from ascending (V1), transverse (V2), descending (V3) and sigmoidal (V4) parts, each having a different pH and flow rate. B) Representative ^{13}C NMR spectrum from the simulated faecal sample with $[\text{U-}^{13}\text{C}]$ labelled PDX. Here, acetate (A), butyrate (B), propionate (P), and valerate (V) were the main metabolites produced during *in vitro* fermentation. C) Representative ^{13}C NMR spectrum of the simulated faecal sample with non-labelled PDX. D) The NMR spectra obtained from the control sample without PDX.

Figure 2. Schematic illustration of compounds produced from $[\text{U-}^{13}\text{C}]$ PDX catabolism. The compound illustrated with dark green stars (★) are the major products of fermentation, while light green stars (★) show the intermediates or the less abundant metabolites in the NMR spectra. The red stars (★) represent the gaseous metabolites detected by GC-MS.

Figure 3. The 60-110 ppm region in representative ^{13}C NMR spectra. Black spectra represent different vessels in the colon simulator while the red spectrum represents a spectrum obtained from pure and undigested substrate. The sharp signal at 104 ppm in PDX (black star) is tentatively assigned to levoglucosan, which is a common by product of PDX formation (through acid-catalysed dehydration). The signal at 107 ppm (green star) most likely is in the same molecule as those at 83, 82, 80.5, 69 and 66 ppm (chemical shifts of a furanose-form). The broad signals at 106-ppm (red star) and 101 ppm (see for instance PDX substrate spectrum) are assigned to β -glucopyranosyl and α -glucopyranosyl units, respectively.

Figure 4. ^{13}CP MAS NMR of simulated fecal pellets. A) Representative ^{13}CP MAS NMR spectrum of simulated fecal pellets. B) PCA score plot and C) Loading plot. The PCA score and loading plot reflects the time/vessels dependent changes in the direction of PC3. The signals from carbohydrate and anomeric resonances decreased from V1 to V4 while carbonyl, CH_2 , CH_3 resonances increased from V1 to V2.

Figure 5. $^{13}\text{CO}_2/^{12}\text{CO}_2$ ratio as determined with GC-MS. The representative plot shows the ratio for a simulation obtained from a single donor.

Figure 6. Correlation coefficients illustrated by heat map. The Pearson correlation coefficient (R) value revealed positive correlation between $^{13}\text{CO}_2/^{12}\text{CO}_2$ ratio and integrals of SCFA signals. Meanwhile the $^{13}\text{CO}_2/^{12}\text{CO}_2$ ratio shows negative correlation to certain region of PDX signals in ^{13}C NMR spectra (PDX1 (104.5-103.9ppm) PDX2 (106.9 – 106.5 ppm) PDX3 (80.8 – 80.5 ppm) PDX4 (69.4-69.2 ppm)). The color-coding in the figure represents the R-values. (× indicates significant correlation p values < 0.05).

Figure 7. Microbial diversity between the three simulations. A) Boxplots show overall α -diversity (diversity within samples) in each simulation using the PD whole tree metric. Groups were compared with a non-parametric t-test using 999 Monte Carlo permutations and the p-value was adjusted using the Benjamini-Hochberg FDR method. Significantly different p values are denoted. B) The β -diversity (diversity between samples) of each simulation is visualized by principal coordinate analysis by weighted UniFrac distance matrix. Colors denote the different simulation numbers: red squares, I; blue circles, II, orange triangles, III. The results were obtained using the ANOSIM statistical method.

Figure 8. Relative abundances of 16S rDNA in all samples at the genus, family (f) or order (o) levels. Samples are ordered by simulation number, simulation time, and the various treatment types: I (inoculum), CTRL (control, without PDX), PDX (2% PDX) and [U- ^{13}C] PDX (^{13}C 2% PDX). The 35 most abundant taxa are shown, with “all other” signifying all other organisms that are <0.2% average abundance. Significant differences are denoted by asterisk (* $p < 0.05$) in order of treatment (CTRL: PDX, CTRL: [U- ^{13}C] PDX), and by simulation number (I/II/ III) following taxa names.

Figure 9. The spearman correlation coefficient (R). The value illustrated by heat map indicate blue is positive correlation while the red gradient indicates negative correlation ($\times$ indicates significant correlation, p values < 0.05).). Here, N represents the natural abundance of given metabolites and the label +1, +2, +3, +4 represents the shifts of the mass of the given metabolite by one, two, three or four units due to ^{13}C label, respectively.

502 References

- 503 1. Sonnenburg, J. L.; Backhed, F., Diet-microbiota interactions as moderators of human
504 metabolism. *Nature* **2016**, *535* (7610), 56-64.
- 505 2. Rooks, M. G.; Garrett, W. S., Gut microbiota, metabolites and host immunity. *Nat Rev*
506 *Immunol* **2016**, *16* (6), 341-352.
- 507 3. Nicholson, J. K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson,
508 S., Host-Gut Microbiota Metabolic Interactions. *Science* **2012**, *336* (6086), 1262-1267.
- 509 4. Nyangale, E. P.; Mottram, D. S.; Gibson, G. R., Gut Microbial Activity, Implications for
510 Health and Disease: The Potential Role of Metabolite Analysis. *J. Proteome Res.* **2012**, *11* (12),
511 5573-5585.
- 512 5. Slavin, J., Fiber and prebiotics: mechanisms and health benefits. *Nutrients* **2013**, *5* (4),
513 1417-35.
- 514 6. Lamichhane, S.; Westerhuis, J. A.; Ouwehand, A. C.; Saarinen, M. T.; Forssten, S. D.;
515 Jensen, H. M.; Young, J. F.; Bertram, H. C.; Yde, C. C., Gut microbial activity as influenced by
516 fiber digestion: dynamic metabolomics in an in vitro colon simulator. *Metabolomics* **2016**, *12*
517 (2), 25.
- 518 7. De Leoz, M. L. A.; Kalanetra, K. M.; Bokulich, N. A.; Strum, J. S.; Underwood, M. A.;
519 German, J. B.; Mills, D. A.; Lebrilla, C. B., Human Milk Glycomics and Gut Microbial
520 Genomics in Infant Feces Show a Correlation between Human Milk Oligosaccharides and Gut
521 Microbiota: A Proof-of-Concept Study. *J. Proteome Res.* **2015**, *14* (1), 491-502.
- 522 8. Scalabrin, D. M.; Mitmesser, S. H.; Welling, G. W.; Harris, C. L.; Marunycz, J. D.;
523 Walker, D. C.; Bos, N. A.; Tolkko, S.; Salminen, S.; Vanderhoof, J. A., New prebiotic blend of
524 polydextrose and galacto-oligosaccharides has a bifidogenic effect in young infants. *J Pediatr*
525 *Gastroenterol Nutr.* **2012**, *54* (3), 343-352.
- 526 9. do Carmo, M. M.; Walker, J. C.; Novello, D.; Caselato, V. M.; Sgarbieri, V. C.;
527 Ouwehand, A. C.; Andreollo, N. A.; Hiane, P. A.; Dos Santos, E. F., Polydextrose: Physiological
528 Function, and Effects on Health. *Nutrients* **2016**, *8* (9), 553.
- 529 10. Oberbach, A.; Haange, S.-B.; Schlichting, N.; Heinrich, M.; Lehmann, S.; Till, H.;
530 Hugenholtz, F.; Kullnick, Y.; Smidt, H.; Frank, K.; Seifert, J.; Jehmlich, N.; von Bergen, M.,
531 Metabolic in Vivo Labeling Highlights Differences of Metabolically Active Microbes from the
532 Mucosal Gastrointestinal Microbiome between High-Fat and Normal Chow Diet. *J. Proteome*
533 *Res.* **2017**, *16* (4), 1593-1604.
- 534 11. de Graaf, A. A.; Maathuis, A.; de Waard, P.; Deutz, N. E.; Dijkema, C.; de Vos, W. M.;
535 Venema, K., Profiling human gut bacterial metabolism and its kinetics using [U-13C]glucose
536 and NMR. *NMR Biomed* **2010**, *23* (1), 2-12.
- 537 12. Yamazawa, A.; Iikura, T.; Shino, A.; Date, Y.; Kikuchi, J., Solid-, Solution-, and Gas-
538 state NMR Monitoring of 13C-Cellulose Degradation in an Anaerobic Microbial Ecosystem.
539 *Molecules* **2013**, *18* (8), 9021.
- 540 13. Butts, C. A.; Paturi, G.; Tavendale, M. H.; Hedderley, D.; Stoklosinski, H. M.; Herath, T.
541 D.; Rosendale, D.; Roy, N. C.; Monro, J. A.; Ansell, J., The fate of 13C-labelled and non-
542 labelled inulin predisposed to large bowel fermentation in rats. *Food Funct.* **2016**, *7* (4), 1825-
543 1832.
- 544 14. Forssten, S. D.; Roytio, H.; Hibberd, A. A.; Ouwehand, A. C., The effect of polydextrose
545 and probiotic lactobacilli in a *Clostridium difficile*-infected human colonic model. *Microb Ecol*
546 *Health Dis.* **2015**, *26*, 27988.

15. van Zanten, G. C.; Knudsen, A.; Roytjo, H.; Forssten, S.; Lawther, M.; Blennow, A.; Lahtinen, S. J.; Jakobsen, M.; Svensson, B.; Jespersen, L., The effect of selected synbiotics on microbial composition and short-chain fatty acid production in a model system of the human colon. *PloS one* **2012**, *7* (10), e47212.
16. Makivuokko, H.; Nurmi, J.; Nurminen, P.; Stowell, J.; Rautonen, N., In vitro effects on polydextrose by colonic bacteria and caco-2 cell cyclooxygenase gene expression. *Nutr. Cancer* **2005**, *52* (1), 94-104.
17. Jacobs, D. M.; Deltimple, N.; van Velzen, E.; van Dorsten, F. A.; Bingham, M.; Vaughan, E. E.; van Duynhoven, J., 1H NMR metabolite profiling of feces as a tool to assess the impact of nutrition on the human microbiome. *NMR Biomed* **2008**, *21* (6), 615-626.
18. Wishart, D. S.; Jewison, T.; Guo, A. C.; Wilson, M.; Knox, C.; Liu, Y.; Djoumbou, Y.; Mandal, R.; Aziat, F.; Dong, E.; Bouatra, S.; Sinelnikov, I.; Arndt, D.; Xia, J.; Liu, P.; Yallou, F.; Bjorn Dahl, T.; Perez-Pineiro, R.; Eisner, R.; Allen, F.; Neveu, V.; Greiner, R.; Scalbert, A., HMDB 3.0--The Human Metabolome Database in 2013. *Nucleic Acids Res* **2013**, *41*(Database issue), 801-807.
19. Savorani, F.; Tomasi, G.; Engelsens, S. B., icoshift: A versatile tool for the rapid alignment of 1D NMR spectra. *J. Magn. Reson.* **2010**, *202* (2), 190-202.
20. Morovic, W.; Hibberd, A. A.; Zabel, B.; Barrangou, R.; Stahl, B., Genotyping by PCR and High-Throughput Sequencing of Commercial Probiotic Products Reveals Composition Biases. *Front Microbiol* **2016**, *7* (1747).
21. Caporaso, J. G.; Kuczynski, J.; Stombaugh, J.; Bittinger, K.; Bushman, F. D.; Costello, E. K.; Fierer, N.; Peña, A. G.; Goodrich, J. K.; Gordon, J. I.; Huttley, G. A.; Kelley, S. T.; Knights, D.; Koenig, J. E.; Ley, R. E.; Lozupone, C. A.; McDonald, D.; Muegge, B. D.; Pirrung, M.; Reeder, J.; Sevinsky, J. R.; Turnbaugh, P. J.; Walters, W. A.; Widmann, J.; Yatsunenko, T.; Zaneveld, J.; Knight, R., QIIME allows analysis of high-throughput community sequencing data. *Nature methods* **2010**, *7* (5), 335-356.
22. Aronesty E. *ea-utils*: Command-line tools for processing biological sequencing. **2011**; data. Available: <http://code.google.com/p/ea-utils>.
23. Edgar, R. C., Search and clustering orders of magnitude faster than BLAST. *Bioinformatics*. **2010**, *26* (19), 2460-1.
24. DeSantis, T. Z.; Hugenholtz, P.; Larsen, N.; Rojas, M.; Brodie, E. L.; Keller, K.; Huber, T.; Dalevi, D.; Hu, P.; Andersen, G. L., Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB. *Appl. Environ. Microbiol.* **2006**, *72* (7), 5069-5072.
25. Caporaso, J. G.; Bittinger, K.; Bushman, F. D.; DeSantis, T. Z.; Andersen, G. L.; Knight, R., PyNAST: a flexible tool for aligning sequences to a template alignment. *Bioinformatics* **2010**, *26* (2), 266-7.
26. Price, M. N.; Dehal, P. S.; Arkin, A. P., FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. *Mol Biol Evol* **2009**, *26* (7), 1641-1650.
27. Faith, D. P.; Baker, A. M., Phylogenetic diversity (PD) and biodiversity conservation: some bioinformatics challenges. *Evol. Bioinform* **2006**, *2*, 121-128.
28. Lozupone, C.; Knight, R., UniFrac: a new phylogenetic method for comparing microbial communities. *Appl. Environ. Microbiol.* **2005**, *71* (12), 8228-8235.
29. Koh, A.; De Vadder, F.; Kovatcheva-Datchary, P.; Bäckhed, F., From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. *Cell* **2016**, *165* (6), 1332-1345.

30. Jie, Z.; Bang-yao, L.; Ming-jie, X.; Hai-wei, L.; Zu-kang, Z.; Ting-song, W.; Craig, S. A. S., Studies on the effects of polydextrose intake on physiologic functions in Chinese people. *Am J Clin Nutr* **2000**, *72* (6), 1503-1509.
31. Beloshapka, A. N.; Wolff, A. K.; Swanson, K. S., Effects of feeding polydextrose on faecal characteristics, microbiota and fermentative end products in healthy adult dogs. *Br. J. Nutr.* **2012**, *108* (4), 638-644.
32. Canani, R. B.; Costanzo, M. D.; Leone, L.; Pedata, M.; Meli, R.; Calignano, A., Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. *World J Gastroenterol* **2011**, *17* (12), 1519-1528.
33. Leonel, A. J.; Alvarez-Leite, J. I., Butyrate: implications for intestinal function. *Curr Opin Clin Nutr Metab Care.* **2012**, *15* (5), 474-479.
34. Fernandes, J.; Su, W.; Rahat-Rozenbloom, S.; Wolever, T. M. S.; Comelli, E. M., Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. *Nutr Diab* **2014**, *4*, e121.
35. Wang, J.; Tang, H.; Zhang, C.; Zhao, Y.; Derrien, M.; Rocher, E.; van-Hylckama Vlieg, J. E.; Strissel, K.; Zhao, L.; Obin, M.; Shen, J., Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. *ISME J.* **2015**, *9* (1), 1-15.
36. De Filippo, C.; Cavalieri, D.; Di Paola, M.; Ramazzotti, M.; Poullet, J. B.; Massart, S.; Collini, S.; Pieraccini, G.; Lionetti, P., Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc. Natl. Acad. Sci. U.S.A* **2010**, *107* (33), 14691-6.
37. Bourriaud, C.; Robins, R. J.; Martin, L.; Kozlowski, F.; Tenailleau, E.; Cherbut, C.; Michel, C., Lactate is mainly fermented to butyrate by human intestinal microfloras but inter-individual variation is evident. *J Appl Microbiol* **2005**, *99* (1), 201-12.
38. Belenguer, A.; Duncan, S. H.; Holtrop, G.; Anderson, S. E.; Lobley, G. E.; Flint, H. J., Impact of pH on lactate formation and utilization by human fecal microbial communities. *Appl. Environ. Microbiol.* **2007**, *73* (20), 6526-33.
39. Macfarlane, S.; Macfarlane, G. T., Regulation of short-chain fatty acid production. *Proc Nutr Soc* **2003**, *62* (1), 67-72.
40. Vodonik, S. A.; Gray, G. R., Analysis by the reductive-cleavage method of linkage positions in a polysaccharide containing 4-linked D-glucopyranosyluronic residues. *Carbohydr. Res.* **1988**, *175* (1), 93-102.
41. Lahtinen, S. J.; Knoblock, K.; Drakoularakou, A.; Jacob, M.; Stowell, J.; Gibson, G. R.; Ouwehand, A. C., Effect of molecule branching and glycosidic linkage on the degradation of polydextrose by gut microbiota. *Biosci. Biotechnol. Biochem* **2010**, *74* (10), 2016-21.
42. Roslund, M. U.; Tahtinen, P.; Niemitz, M.; Sjöholm, R., Complete assignments of the (1)H and (13)C chemical shifts and J(H,H) coupling constants in NMR spectra of D-glucopyranose and all D-glucopyranosyl-D-glucopyranosides. *Carbohydr. Res.* **2008**, *343* (1), 101-12.
43. Satoh, T.; Imai, T.; Ishihara, H.; Maeda, T.; Kitajyo, Y.; Sakai, Y.; Kaga, H.; Kaneko, N.; Ishii, F.; Kakuchi, T., Synthesis, Branched Structure, and Solution Property of Hyperbranched d-Glucan and d-Galactan. *Macromolecules* **2005**, *38* (10), 4202-4210.
44. Jain, D.; Stark, A. Y.; Niewiarowski, P. H.; Miyoshi, T.; Dhinojwala, A., NMR spectroscopy reveals the presence and association of lipids and keratin in adhesive gecko setae. *Sci. Rep.* **2015**, *5*, 9594.

45. Pimentel, M.; Gunsalus, R. P.; Rao, S. S. C.; Zhang, H., Methanogens in Human Health and Disease. *Am J Gastroenterol Suppl* **2012**, *1* (1), 28-33.
46. Kaakoush, N. O., Insights into the Role of Erysipelotrichaceae in the Human Host. *Front Cell Infect Microbiol* **2015**, *5* (84).
47. Zhang, C.; Zhang, M.; Wang, S.; Han, R.; Cao, Y.; Hua, W.; Mao, Y.; Zhang, X.; Pang, X.; Wei, C.; Zhao, G.; Chen, Y.; Zhao, L., Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. *ISME J* **2010**, *4* (2), 232-41.
48. Zhu, Q.; Jin, Z.; Wu, W.; Gao, R.; Guo, B.; Gao, Z.; Yang, Y.; Qin, H., Analysis of the intestinal lumen microbiota in an animal model of colorectal cancer. *PloS one* **2014**, *9* (6), e90849.
49. Craven, M.; Egan, C. E.; Dowd, S. E.; McDonough, S. P.; Dogan, B.; Denkers, E. Y.; Bowman, D.; Scherl, E. J.; Simpson, K. W., Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease. *PloS one* **2012**, *7* (7), e41594.
50. Martinez, I.; Perdicaro, D. J.; Brown, A. W.; Hammons, S.; Carden, T. J.; Carr, T. P.; Eskridge, K. M.; Walter, J., Diet-induced alterations of host cholesterol metabolism are likely to affect the gut microbiota composition in hamsters. *Appl. Environ. Microbiol.* **2013**, *79* (2), 516-24.
51. Umu, Ö. C. O.; Frank, J. A.; Fangel, J. U.; Oostindjer, M.; da Silva, C. S.; Bolhuis, E. J.; Bosch, G.; Willats, W. G. T.; Pope, P. B.; Diep, D. B., Resistant starch diet induces change in the swine microbiome and a predominance of beneficial bacterial populations. *Microbiome* **2015**, *3* (1), 16.
52. Cox, L. M.; Cho, I.; Young, S. A.; Anderson, W. H. K.; Waters, B. J.; Hung, S.-C.; Gao, Z.; Mahana, D.; Bihan, M.; Alekseyenko, A. V.; Methé, B. A.; Blaser, M. J., The nonfermentable dietary fiber hydroxypropyl methylcellulose modulates intestinal microbiota. *FASEB J* **2013**, *27* (2), 692-702.
53. Vital, M.; Howe, A. C.; Tiedje, J. M., Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. *mBio* **2014**, *5* (2), e00889.
54. Pozuelo, M.; Panda, S.; Santiago, A.; Mendez, S.; Accarino, A.; Santos, J.; Guarner, F.; Azpiroz, F.; Manichanh, C., Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. *Sci. Rep.* **2015**, *5*, 12693.
55. Lecomte, V.; Kaakoush, N. O.; Maloney, C. A.; Raipuria, M.; Huinao, K. D.; Mitchell, H. M.; Morris, M. J., Changes in Gut Microbiota in Rats Fed a High Fat Diet Correlate with Obesity-Associated Metabolic Parameters. *PloS one* **2015**, *10* (5), e0126931.
56. Turnbaugh, P. J.; Backhed, F.; Fulton, L.; Gordon, J. I., Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. *Cell host microbe* **2008**, *3* (4), 213-23.
57. Duvallet, C.; Gibbons, S. M.; Gurry, T.; Irizarry, R. A.; Alm, E. J., Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. *Nat. Commun.* **2017**, *8* (1), 1784.
58. Wu, G. D.; Chen, J.; Hoffmann, C.; Bittinger, K.; Chen, Y. Y.; Keilbaugh, S. A.; Bewtra, M.; Knights, D.; Walters, W. A.; Knight, R.; Sinha, R.; Gilroy, E.; Gupta, K.; Baldassano, R.; Nessel, L.; Li, H.; Bushman, F. D.; Lewis, J. D., Linking long-term dietary patterns with gut microbial enterotypes. *Science* **2011**, *334* (6052), 105-8.
59. Zhang, C.; Zhao, L., Strain-level dissection of the contribution of the gut microbiome to human metabolic disease. *Genome Medicine* **2016**, *8*, 41.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

60. Takahashi, K.; Nishida, A.; Fujimoto, T.; Fujii, M.; Shioya, M.; Imaeda, H.; Inatomi, O.; Bamba, S.; Sugimoto, M.; Andoh, A., Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease. *Digestion* **2016**, *93* (1), 59-65.

61. Rajilic-Stojanovic, M.; de Vos, W. M., The first 1000 cultured species of the human gastrointestinal microbiota. *FEMS Microbiol Rev.* **2014**, *38* (5), 996-1047.

62. Polansky, O.; Sekelova, Z.; Faldynova, M.; Sebkova, A.; Sisak, F.; Rychlik, I., Important Metabolic Pathways and Biological Processes Expressed by Chicken Cecal Microbiota. *Appl. Environ. Microbiol.* **2015**, *82* (5), 1569-76.

63. Flint, H. J.; Duncan, S. H.; Scott, K. P.; Louis, P., Links between diet, gut microbiota composition and gut metabolism. *Proc Nutr Soc* **2015**, *74* (1), 13-22.

64. Coakley, M.; Ross, R. P.; Nordgren, M.; Fitzgerald, G.; Devery, R.; Stanton, C., Conjugated linoleic acid biosynthesis by human-derived *Bifidobacterium* species. *J Appl Microbiol* **2003**, *94* (1), 138-45.

65. Riviere, A.; Selak, M.; Lantin, D.; Leroy, F.; De Vuyst, L., *Bifidobacteria* and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. *Front Microbiol.* **2016**, *7*, 979.

66. De Vuyst, L.; Leroy, F., Cross-feeding between *bifidobacteria* and butyrate-producing colon bacteria explains *bifidobacterial* competitiveness, butyrate production, and gas production. *Int J Food Microbiol* **2011**, *149* (1), 73-80.

FIGURE 1.

FIGURE 2.

FIGURE 3.

FIGURE 4.

FIGURE 5.

FIGURE 6.

FIGURE 7.

FIGURE 8.

FIGURE 9.

"for TOC only"

151x145mm (300 x 300 DPI)